Active Recombinant Human CD22, Fc-tagged, Biotinylated
Cat.No. : | CD22-560H |
Product Overview : | The recombinant human CD22-Fc fusion protein is expressed as an 892 amino acid protein consisting of Asp20 - Thr683 region of CD22 (UniProt accession #P20273) and a C-terminal Fc fusion from human IgG1, which exists as a dimer under non-reducing condition. |
- Specification
- Gene Information
- Related Products
Source : | Human cells |
Species : | Human |
Tag : | Fc |
Form : | Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free). The purified recombinant protein was labeled with Biotin (3-5 Biotin per molecule). |
Bio-activity : | Immobilized CD22 ECD protein supports the adhesion of human red blood cells. Binds anti-CD22 monoclonal antibodies with high affinity. |
Molecular Mass : | Calculated molecular mass (kDa): 100.2; Estimated by SDS-PAGE under reducing condition (kDa): 120-130 probably due to glycosylation |
AA Sequence : | DSSKWVFEHPETLYAWEGACVWIPC TYRALDGDLESFILFHNPEYNKNTS KFDGTRLYESTKDGKVPSEQKRVQF LGDKNKNCTLSIHPVHLNDSGQLGL RMESKTEKWMERIHLNVSERPFPPH IQLPPEIQESQEVTLTCLLNFSCY GYPIQLQWLLEGVPMRQAAVTSTSL TIKSVFTRSELKFSPQWSHHGKIVT CQLQDADGKFLSNDTVQLNVKHTP KLEIKVTPSDAIVREGDSVTMTCEV SSSNPEYTTVSWLKDGTSLKKQNTF TLNLREVTKDQSGKYCCQVSNDVG PGRSEEVFLQVQYAPEPSTVQILHS PAVEGSQVEFLCMSLANPLPTNYTW YHNGKEMQGRTEEKVHIPKILPWH AGTYSCVAENILGTGQRGPGAELDV QYPPKKVTTVIQNPMPIREGDTVTL SCNYNSSNPSVTRYEWKPHGAWEE PSLGVLKIQNVGWDNTTIACAACNS WCSWASPVALNVQYAPRDVRVRKIK PLSEIHSGNSVSLQCDFSSSHPKE VQFFWEKNGRLLGKESQLNFDSISP EDAGSYSCWVNNSIGQTASKAWTLE VLYAPRRLRVSMSPGDQVMEGKSA TLTCESDANPPVSHYTWFDWNNQSL PYHSQKLRLEPVKVQHSGAYWCQGT NSVGKGRSPLSTLTVYYSPETSTG THTCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREP QVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLS PGK |
Endotoxin : | <0.1 eu per 1 μg of purified recombinant protein determined by the |
Purity : | >90% judged by SDS-PAGE under reducing condition |
Storage : | The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks. Avoid repeated freeze-thaw cycles. |
Gene Name : | CD22 CD22 molecule [ Homo sapiens ] |
Official Symbol : | CD22 |
Synonyms : | CD22; CD22 molecule; CD22 antigen; B-cell receptor CD22; sialic acid binding Ig like lectin 2; SIGLEC 2; SIGLEC2; BL-CAM; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2; SIGLEC-2; FLJ22814; MGC130020; |
Gene ID : | 933 |
mRNA Refseq : | NM_001185099 |
Protein Refseq : | NP_001172028 |
MIM : | 107266 |
UniProt ID : | P20273 |
Chromosome Location : | 19q13.1 |
Pathway : | B Cell Receptor Signaling Pathway, organism-specific biosystem; B cell receptor signaling pathway, organism-specific biosystem; B cell receptor signaling pathway, conserved biosystem; BCR signaling pathway, organism-specific biosystem; Cell adhesion molecules (CAMs), organism-specific biosystem; Cell adhesion molecules (CAMs), conserved biosystem; Hematopoietic cell lineage, organism-specific biosystem; |
Function : | protein binding; sugar binding; |
Products Types
◆ Lysates | ||
CD22-001MCL | Recombinant Mouse CD22 cell lysate | +Inquiry |
CD22-1956HCL | Recombinant Human CD22 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionCD22-targeted immunotherapy is more targeted, specifically attacking cancer cells, whereas chemotherapy affects both healthy and cancerous cells.
Yes, CD22-targeted therapies are often used in combination with chemotherapy or other immunotherapies for enhanced efficacy.
CD22-targeted therapies are being explored for autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus.
Yes, CD22 is targeted in immunotherapy for B cell malignancies like acute lymphoblastic leukemia (ALL).
CD22 acts as an inhibitory receptor, regulating B cell activation and signaling.
Customer Reviews (3)
Write a reviewThe CD22 protein offers numerous advantages in trials and research studies, making it an excellent choice for scientists in need of reliable and high-quality experimental materials.
Its unique properties make CD22 an invaluable tool for investigating cellular signaling pathways, protein-protein interactions, and membrane dynamics.
With the CD22 protein and its accompanying technical assistance, I am confident that I can achieve successful outcomes for my research endeavors.
Ask a Question for All CD22 Products
Required fields are marked with *
My Review for All CD22 Products
Required fields are marked with *
Inquiry Basket